Treatment with FAK inhibitors has demonstrated significant efficacy against CDH1-deficient gastric cancer, characterized by downregulated E-cadherin and damaged membrane E-cadherin/β-catenin protein complexes a, resulting in reduced sensitivity of tumor cells to chemotherapy. The gene discussed is CDH1; the disease is neoplasm.